- Novo’s Wegovy beats Lilly’s Zepbound in real-world study for heart diseases Seeking Alpha
- Weight loss drugs can halve heart patients’ risk of early death, study finds The Guardian
- Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease PR Newswire
- Weight loss jabs could keep heart failure patients out of hospital The Independent
- Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas Yahoo Finance
Source link
